Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Primary Biliary Cirrhosis

Conditions

Primary Biliary Cirrhosis

Trial Timeline

Aug 1, 2007 → Aug 1, 2010

About Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)

Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) is a phase 2 stage product being developed by Shionogi for Primary Biliary Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00575042. Target conditions include Primary Biliary Cirrhosis.

What happened to similar drugs?

20 of 20 similar drugs in Primary Biliary Cirrhosis were approved

Approved (20) Terminated (6) Active (0)
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
Duloxetine + PlaceboEli LillyApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
Eszopiclone + PlaceboSumitomo PharmaApproved
RosuvastatinAstraZenecaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00575042Phase 2Completed

Competing Products

20 competing products in Primary Biliary Cirrhosis

See all competitors
ProductCompanyStageHype Score
Unfractionated heparinSinopharmPre-clinical
33
azenosertibZentalis PharmaceuticalsPhase 2
32
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
REN001OnKure TherapeuticsPhase 1
11
Mavodelpar + PlaceboOnKure TherapeuticsPhase 2
25
REN001OnKure TherapeuticsPhase 2/3
20
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
Rituximab + Methotrexate + Cytarabine InjectionCelltrionPhase 2
31
Rituximab, lenalidomideCelltrionPhase 2
42
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
CS-3150Daiichi SankyoPre-clinical
26
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPre-clinical
33
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Combination of bempedoic acid and ezetimibeDaiichi SankyoPre-clinical
33
DS-8201a + T-DM1Daiichi SankyoPhase 3
44
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
18
Roxadustat + PlaceboAstellas PharmaPhase 3
32
Enzalutamide + ExemestaneAstellas PharmaPhase 2
35
Bocidelpar + PlaceboAstellas PharmaPhase 2
27
Methotrexate + Ibrutinib + TemozolomideSun PharmaceuticalPhase 2
31